Anzeige
Mehr »
Dienstag, 29.07.2025 - Börsentäglich über 12.000 News
Warum Analysten in diesem veganen Gamechanger viel mehr sehen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DJVB | ISIN: FR0014005I80 | Ticker-Symbol: G3O
Frankfurt
28.07.25 | 17:18
7,550 Euro
-9,04 % -0,750
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
S.M.A.I.O SA Chart 1 Jahr
5-Tage-Chart
S.M.A.I.O SA 5-Tage-Chart

Aktuelle News zur S.M.A.I.O SA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
16.07.SMAIO Announces Significant Sales Increase in H1 2025232Sales H1 2025: +126% to €5 million Acceleration of business activity in the United States (+360% to €3.8 million): H1 2025 sales1 higher than full-year 2024 sales More than...
► Artikel lesen
12.05.SMAIO Announces the Finalization of a €2.5 Million Fund-Raising, Consisting of a €1.5 Million Capital Increase and a €1 Million Convertible Bond Issue318The transaction was fully subscribed by NextStage AM, in accordance with the terms previously communicated Regulatory News: This press release may not be published, distributed or disseminated...
► Artikel lesen
15.04.SMAIO Announces a €2.5 Million Fund-Raising, Consisting of a €1.5 Million Capital Increase and a €1 Million Convertible Bond Issue429Regulatory News: This press release may not be published, distributed or disseminated, directly or indirectly, in the United States of America or Canada, Australia, Japan or South Africa. SMAIO...
► Artikel lesen
S.M.A.I.O SA Aktie jetzt für 0€ handeln
15.04.SMAIO Announces Consolidated Results for 2024 and Record Sales Performance in Q1 2025337Sharp increase in sales, up +114%1 to €5.5 million in 2024 and +140% to €2.5 million in Q1 2025 Improvement in the margin rate on implant sales to 79% in 2024, vs. 71% at the end of 2023...
► Artikel lesen
28.02.SMAIO Adds a New High-Profile Member to Its Scientific Advisory Board in the United States420Appointment of Dr. Donald J. Blaskiewicz, neurosurgeon at St. Luke's Clinic in Boise (Idaho) SMAIO's U.S. scientific advisory board now includes three North American surgeons, and is set...
► Artikel lesen
27.01.SMAIO Provides Update on Its Partnership With NuVasive and Confirms Its Strategic Focus on the U.S. Market278Regulatory News: SMAIO (Software, Machines and Adaptative Implants in Orthopaedics Euronext Growth Paris, ISIN: FR0014005I80 Ticker: ALSMA), a French-American player specialized in complex spine...
► Artikel lesen
21.01.SMAIO Announces 2024 Sales of €5.5m, More Than Half of Which Generated in the United States466Implant sales growth in excess of 100%, thanks to a strategic focus on the US market, driving strong revenue growth which is now mainly generated in the United States Establishment of the Group's...
► Artikel lesen
06.01.SMAIO: 2025 Financial Calendar318Regulatory News: SMAIO (Software, Machines and Adaptative Implants in Orthopaedics Euronext Growth Paris ISIN: FR0014005I80 Ticker: ALSMA, PEA-PME eligible), a French player specialized in complex...
► Artikel lesen
15.10.24SMAIO Publishes Its First-half 2024 Results and Announces the Creation of a High-profile Scientific Advisory Board to Support Its Development in the United States413Sales of implants and instruments up +81% to €2.2 million Margin on implant sales up sharply to 79% from 71% at end 2023, driven by the ramp-up of surgeries in the United States Good...
► Artikel lesen
9 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1